Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.7 |
mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.7 |
mRNA | Bleomycin | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
mRNA | XMD8-85 | GDSC1000 | pan-cancer | AAC | 0.026 | 0.7 |
mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | -0.025 | 0.7 |
mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.7 |